Other Information
−Removed: During the three months ended March 31, 2025, one of the Company's directors and officers adopted, modified or terminated a “ Rule 10b5-1 trading arrangement” or a “ non-Rule 10b5-1 trading arrangement” as each term is defined under Item 408 of Regulation S-K.
−Removed: On March 15, 2025 , Keith Pfeil , the Company’s Executive Vice President, Chief Operating Officer and Chief Financial Officer , modified a trading arrangement for the sale of securities of the Company’s Class A Common that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) (a “Rule 10b5-1 Trading Plan”).
−Removed: Pfeil’s Rule 10b5-1 Trading Plan, which had a term ending upon the earlier of March 15 ,2025, or the sale of all shares subject to the plan was extended, to terminate upon the earlier of March 15, 2026, or the sale of all shares subject to the plan, and provides for the sale of up to 165,625 shares of Class A Common pursuant to the terms of the plan.
+Added: During the three months ended June 30, 2025, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933).
The following is a list of exhibits filed as part of this Quarterly Report on Form 10-Q.
3 unchanged sentences
and Palmer Merger Sub, Inc.
−Removed: (incorporated by reference to Exhibit 2.1 to Globus Medical, Inc.’s Current Report on Form 8-K filed February 6, 2025)***
−Removed: Voting and Support Agreement, dated as of February 6, 2025, by and among Globus Medical, Inc., Nevro Corp., and other signatories thereto.
−Removed: (incorporated by reference to Exhibit 10.1 to Globus Medical, Inc.’s Current Report on Form 8-K filed February 6, 2025)***
+Added: (incorporated by reference to Exhibit 2.1 to Globus’s Current Report on Form 8-K filed on February 6, 2025).
+Added: 2021 Equity Incentive Plan as amended (incorporated by reference to Exhibit 10.1 to our Form 8-K filed on June 5, 2025).
+Added: Guaranty, dated as of September 27, 2023, by and among U.S.
+Added: Bank National Associations, as administrative agent, and Nevro Corp., as guarantors (incorporated herein by reference to Exhibit 2.1 to Globus's Current Report on Form 8-K filed with the SEC on February 6, 2025).
Certification by Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
15 unchanged sentences
GLOBUS MEDICAL, INC.
−Removed: /s/ DANIEL T.
+Added: August 7, 2025
+Added: /s/ KEITH PFEIL
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: /s/ KEITH PFEIL
−Removed: Chief Financial Officer and Chief Operating Officer
−Removed: Chief Accounting Officer
−Removed: Executive Vice President
+Added: August 7, 2025
+Added: /s/ KYLE KLINE
+Added: Chief Financial Officer
(Principal Financial Officer)
+Added: Senior Vice President
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.